ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-IGSF8 Monoclonal Antibody GV20-0251

Its studies are mostly in Neoplasms · Uterine Cervical Neoplasms, led by GV20 Therapeutics.

Drug pageAnti-IGSF8 Monoclonal Antibody GV20-0251: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 12, 20223 company-led studies, 3 open or runningNext primary completion: Dec 15, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GV20 Therapeutics33 open or runningphase 2since Dec 12, 2022Dec 12, 2022Dec 15, 2026phase 2 · NCT05669430

Also a collaborator on its studies: Merck.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 12, 2022First study: phase 2 study in NeoplasmsFirst studyNCT05669430 · 365 planned · United States
  2. Jun 26, 2025Phase 2 study in NeoplasmsNCT07070518 · 350 planned · China
  3. May 29, 2026Phase 2 study in Uterine Cervical NeoplasmsNCT07623642 · 227 planned · China

Ahead

  1. Dec 15, 2026Primary completion: phase 2 study in NeoplasmsNCT05669430
  2. Jul 16, 2027Primary completion: phase 2 study in NeoplasmsNCT07070518
  3. Jun 15, 2028Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT07623642

TargetBeta

IGSF8 →read by rule
“A human, Fc-attenuated immunoglobulin G1 (IgG1) monoclonal antibody targeting the immune checkpoint immunoglobulin superfamily member 8 (IGSF8; PGRL; PG regulatory-like protein, KCT-4, CD81 partner 3; LIR-D1; KASP; KAI/CD82 associated protein; EWI-2; Glu-Trp-Ile EWI motif-containing protein 2), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623642Uterine Cervical Neoplasms · China2Not yet recruitingJun 15, 2028227
NCT07070518Neoplasms · China2RecruitingJul 16, 2027350
NCT05669430Neoplasms · United States2RecruitingDec 15, 2026365

How it is read

Names in the registry

  • “GV20-0251”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.